TSK STERiJECT Ophthalmic Needle (VLDS)

FDA 510(k) cleared for ophthalmic use.

The STERiJECT Ophthalmic Low Dead Space Needle's FDA 510(k) has been cleared, compliant with testing to ophthalmic standards such as USP 789 (788). The sharp increase in retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy, and retinal vein occlusion has led to a surge in intravitreal injection procedures. Despite this, many practices still rely on hypodermic needles not originally intended for use in the eye. STERiJECT™ was created to meet this unmet clinical need—offering a dedicated device for ophthalmologists and retina specialists that prioritizes dose control, patient comfort, and sterility. 

Minimal redundant hub space
The Ophthalmic low dead space needle is engineered to minimize the amount of fluid retained in the needle hub after an injection, effectively reducing residual volume to near zero. By optimizing the hub design, this patented Low Dead Space (LDS) technology significantly reduces wasted medication. Each low residual needle can save up to 0.042ml per hypodermic injection, which adds up to substantial savings when administering high-value drugs. For practitioners, this means maximizing the delivered dose while minimizing product loss, ensuring both cost efficiency and precision in clinical treatments.

Significant product and cost savings
Using a low dead space needle provides measurable benefits for both product conservation and financial savings. The advanced LDS hub design minimizes leftover medication, making it ideal for high-cost treatments or precious pharmaceuticals such as ophthalmic drugs, aesthetic treatment injections, or vaccines, including COVID-19 vaccines. By reducing residual fluid in the hub, each injection ensures that more of the medication reaches the patient, cutting down on waste and lowering overall treatment costs. In this way, the low residual needle is not only clinically efficient but also economically advantageous for healthcare providers.

Larger inner diameter with TSKiD™ Large
Larger low dead space needles are equipped with TSKiD™ Large barrels, incorporating enlarged inner diameters to optimize flow and injection performance. TSK has developed this specialized TSKiD™ technology in three variations—Standard, Large, and Max—allowing practitioners to choose the appropriate diameter for specific applications. For instance, a 30G needle with TSKiD™ Max barrels can increase the inner diameter by up to 65% compared to ISO standards. This enhanced diameter allows smoother product delivery, reduces injection force, and complements the low residual needle design by ensuring minimal product retention while maintaining precise, controlled injections.

External 360 hub threading
The low dead space needle also features external 360-degree hub threading for an exceptionally secure luer lock connection. This design prevents accidental “pop-off” of the hub under high-pressure conditions, providing practitioners with confidence during delicate or high-viscosity injections. When combined with the LDS hub design, the external threading ensures that medication is delivered safely, efficiently, and reliably every time.

Hard polymer hub
Durability and stability are critical in high-precision injections, which is why low residual needle hubs are manufactured from an extremely hard polymer. This rigid material prevents flexing or deformation of the hub when exposed to high pressures, ultimately reducing the risk of leakage or needle detachment. The combination of a hard polymer hub and LDS design ensures that each low dead space needle delivers consistent, predictable, and efficient results, making it an essential tool for modern medical and aesthetic procedures.